Subtopic Deep Dive
Epidemiology of Myasthenia Gravis and Thymoma
Research Guide
What is Epidemiology of Myasthenia Gravis and Thymoma?
Epidemiology of Myasthenia Gravis and Thymoma studies incidence, prevalence, risk factors, geographic variations, and thymoma associations in myasthenia gravis patients.
Incidence rates range from 4.1 to 30 cases per million person-years, with prevalence from 150 to higher estimates reflecting improved ascertainment (Dresser et al., 2021, 401 citations). Population studies show marked variation in MG frequencies, increasing with study year and quality (Carr et al., 2010, 732 citations). Early data from Amsterdam reported annual incidence of 3.1 and prevalence of 53 per million in 1961-65 (Oosterhuis, 1989, 326 citations).
Why It Matters
Epidemiological data guide public health screening for at-risk groups, such as older adults where underdiagnosis occurs, as shown by high unrecognized AChR antibodies in those ≥75 years (Vincent, 2003, 228 citations). Insights into rising incidence trends inform etiology research and resource allocation (Carr et al., 2010). Understanding thymoma-MG links supports targeted tumor screening, improving early intervention outcomes (Melzer et al., 2016).
Key Research Challenges
Underdiagnosis in Elderly
Clinically recognized MG incidence drops sharply over age 80 despite high unrecognized AChR antibodies (Vincent, 2003). This biases prevalence estimates and delays treatment. Improved serological screening is needed for accurate epidemiology.
Geographic Variation
Marked differences in observed MG frequencies across populations lack full explanation beyond ascertainment (Carr et al., 2010). Genetic and environmental factors require multi-center studies. Standardized methodologies are essential.
Thymoma Association Trends
Quantifying thymoma prevalence in MG subtypes remains inconsistent across eras. Long-term follow-up shows evolving patterns (Oosterhuis, 1989). Modern imaging and biopsy data integration is critical.
Essential Papers
A systematic review of population based epidemiological studies in Myasthenia Gravis
Aisling Carr, Chris R. Cardwell, Peter O McCarron et al. · 2010 · BMC Neurology · 732 citations
We report marked variation in observed frequencies of MG. We show evidence of increasing frequency of MG with year of study and improved study quality. This probably reflects improved case ascertai...
Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype
Emily K. Mathey, Susanna B. Park, Richard AC Hughes et al. · 2015 · Journal of Neurology Neurosurgery & Psychiatry · 410 citations
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an inflammatory neuropathy, classically characterised by a slowly progressive onset and symmetrical, sensorimotor involvement. Ho...
Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations
Laura Dresser, Richard Wlodarski, Kourosh Rezania et al. · 2021 · Journal of Clinical Medicine · 401 citations
Myasthenia gravis (MG) is an autoimmune neurological disorder characterized by defective transmission at the neuromuscular junction. The incidence of the disease is 4.1 to 30 cases per million pers...
The natural course of myasthenia gravis: a long term follow up study.
Harry Oosterhuis · 1989 · Journal of Neurology Neurosurgery & Psychiatry · 326 citations
A long term follow up study is presented of 73 patients with myasthenia gravis, living in Amsterdam between 1926 and 1965. In the period 1961-65 the annual incidence was 3.1, the prevalence 53 per ...
Regulatory T cells in multiple sclerosis and myasthenia gravis
K. M. Danikowski, Sundararajan Jayaraman, Bellur S. Prabhakar · 2017 · Journal of Neuroinflammation · 311 citations
Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society
Nico Melzer, Tobias Ruck, Peter Fuhr et al. · 2016 · Journal of Neurology · 268 citations
Evidence of underdiagnosis of myasthenia gravis in older people
Angela Vincent · 2003 · Journal of Neurology Neurosurgery & Psychiatry · 228 citations
The sharp fall in the incidence of clinically recognised myasthenia gravis in people over 80 years of age in our national AChR antibody incidence study, and the high prevalence of previously unreco...
Reading Guide
Foundational Papers
Start with Carr et al. (2010, 732 citations) for systematic review of incidence variations; Oosterhuis (1989, 326 citations) for baseline prevalence data; Vincent (2003, 228 citations) for elderly underdiagnosis evidence.
Recent Advances
Dresser et al. (2021, 401 citations) for updated incidence/prevalence; Melzer et al. (2016, 268 citations) for clinical features including thymoma associations.
Core Methods
Population registries for ascertainment (Carr et al., 2010); AChR antibody serology (Vincent, 2003); long-term cohort follow-up (Oosterhuis, 1989).
How PapersFlow Helps You Research Epidemiology of Myasthenia Gravis and Thymoma
Discover & Search
Research Agent uses searchPapers and citationGraph to map Carr et al. (2010, 732 citations) as the central node, revealing 50+ epidemiological studies with rising incidence trends. exaSearch uncovers geographic clusters; findSimilarPapers links to Dresser et al. (2021) for prevalence updates.
Analyze & Verify
Analysis Agent applies readPaperContent to extract incidence rates from Oosterhuis (1989), then runPythonAnalysis with pandas to plot age-prevalence trends across Carr et al. (2010) datasets. verifyResponse (CoVe) and GRADE grading confirm underdiagnosis claims in Vincent (2003) against contradictory reports.
Synthesize & Write
Synthesis Agent detects gaps in thymoma epidemiology post-2010, flagging contradictions in prevalence rises. Writing Agent uses latexEditText, latexSyncCitations for Carr et al. (2010) and Dresser et al. (2021), latexCompile for reports, and exportMermaid for incidence timeline diagrams.
Use Cases
"Plot MG incidence trends by study year from population studies"
Research Agent → searchPapers('MG epidemiology incidence') → Analysis Agent → runPythonAnalysis(pandas plot from Carr 2010 + Oosterhuis 1989 data) → matplotlib trend graph with R² fit.
"Draft LaTeX review on MG prevalence geographic variations"
Synthesis Agent → gap detection → Writing Agent → latexEditText(structured sections) → latexSyncCitations(Carr 2010, Dresser 2021) → latexCompile → PDF with embedded tables.
"Find code for analyzing MG antibody seroprevalence stats"
Research Agent → paperExtractUrls(Vincent 2003) → Code Discovery → paperFindGithubRepo → githubRepoInspect → R script for AChR positivity rates by age group.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ MG epidemiology) → citationGraph → DeepScan(7-step verification with GRADE on Carr 2010). Theorizer generates hypotheses on thymoma risk from Oosterhuis (1989) follow-up + Dresser (2021) data. Chain-of-Verification/CoVe ensures prevalence claims match Vincent (2003) evidence.
Frequently Asked Questions
What is the definition of MG epidemiology?
Epidemiology of Myasthenia Gravis examines incidence (4.1-30/million person-years), prevalence (150+ per million), risk factors, and thymoma associations using population studies (Dresser et al., 2021).
What are key methods in MG epidemiology?
Population-based studies use case ascertainment via registries and AChR antibody testing; systematic reviews aggregate incidence trends (Carr et al., 2010). Long-term follow-up tracks natural course (Oosterhuis, 1989).
What are the most cited papers?
Carr et al. (2010, 732 citations) reviews epidemiological studies showing rising frequencies; Oosterhuis (1989, 326 citations) reports Amsterdam incidence of 3.1/million; Dresser et al. (2021, 401 citations) updates pathophysiology and rates.
What are open problems?
Underdiagnosis in elderly (Vincent, 2003), unexplained geographic variations (Carr et al., 2010), and evolving thymoma-MG links need better global registries and genetic studies.
Research Myasthenia Gravis and Thymoma with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Epidemiology of Myasthenia Gravis and Thymoma with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Myasthenia Gravis and Thymoma Research Guide